Inclusion Criteria:

- Histological or cytological confirmed locally advanced NSCLC (stage IIIA/B) not
suitable for curative treatment or metastatic (stage IV) NSCLC

- Newly diagnosed patients with locally advanced and/or metastatic NSCLC who are
systemic treatment Naive (i.e. no chemotherapy or EGFR-TKI) or patients with
recurrent disease who have previously received adjuvant chemotherapy (not including
EGFR-TKI)

- Provision of diagnostic cancer tissue or cytology sample upon inclusion (surgical
specimen, biopsy sample, or cytology sample is acceptable) and Provision of a routine
blood (plasma) sample in China, Russia, Taiwan and Korea

- Patients aged 18 years and older

Exclusion Criteria:

- As judged by the investigator, any evidence of severe or uncontrolled systemic
disease (e.g. unstable or uncompensated respiratory, cardiac, hepatic or renal
disease)

- Evidence of any other significant clinical disorder or laboratory finding that made
it undesirable for the patient to participate in the study

- Pregnancy or breast-feeding